Rilonacept to Improve Artery Function in Patients With Atherosclerosis

Exclusion Criteria

• •BMI (body mass index) greater than 49.9 kg/m2 at Screening Visit 1 -Vascular intervention within 60 days prior to Screening Visit 1.
• •Infection, use of systemic antibiotics, or clinically significant trauma (including surgery) within 30 days prior to Screening Visit 1.
• •History or evidence of acute coronary syndrome within 60 days prior to Screening Visit 1.
• •Acute or chronic inflammatory condition other than atherosclerosis
• •Recently diagnosed diabetes mellitus
• •Clinical evidence of congestive heart failure NYHA Class III-IV
• •History of hypersensitivity other than localized injection site reaction to any biologic agent.
• •Use of a thiazolidinedione
• •Use of immunosuppressive or immunomodulatory medication (use of an inhaled glucocorticoid is permitted).
• •Prior use of an immunomodulatory biologic drug within the last 6 months except immunizations and biologics used as standard care in cardiac care settings.
• •Received a live/live attenuated vaccine within 90 days prior to Screening Visit 1 or other immunization within 30 days prior to Screening Visit 1.
• •Prior or planned organ transplant recipient.
• •Severe respiratory disease
• •A history of tuberculosis infection, history of a positive skin test for tuberculosis, or a chest radiograph at Screening Visit 1 consistent with prior tuberculosis infection
• •Positive result (5 mm or more in duration at 48 to 72 hours post-placement) of the PPD 5 TU placed at Screening Visit 2
• •History or presence of malignancy (except for successfully treated basal cell carcinoma of the skin or in situ carcinoma of the cervix) within the past 5 years.
• •HIV positive.
• •Hepatitis B surface antigen or Hepatitis C antibody positive
• •ALT, AST or alkaline phosphatase greater than twice the upper limit of the normal range, serum creatinine or total bilirubin greater than 1.5 times the upper limit of normal at Screening Visit 1.
• •Hemoglobin less than 11.0 gm/dL, white blood cell (WBC) count less than 3,000/mm3, neutrophil count less than 2000/mm3 or platelet count less than 100,000/mm3 at Screening Visit 1.
• •Participation in any clinical research study evaluating another investigational drug or therapy within 30 days prior to Screening Visit 1.
• •History of substance abuse
• •Elective surgery or vascular intervention planned to occur during the study.
• •Any medical condition which would interfere with participation in the study, interfere with interpretation of study outcome measures, or place the subject at risk.